Dr. Moshe Talpaz''Moshe Talpaz, M.D., Associate Chief, Division of Hematology/Oncology, is a leading clinical investigator in hematologic malignancies. Dr. Talpaz focuses on the treatment of chronic myelogenous leukemia (CML) and brings special expertise in immunotherapy, cytokines and biologic response modifiers. Internationally known for his role in the development of targeted cancer therapeutics, Dr. Talpaz pioneered the study of interferon in CML, which was the first line therapy for CML until the introduction of STI571 (Gleevec). As a pivotal member of the team that developed Gleevec, Dr. Talpaz was instrumental in bringing to market one of the most effective targeted treatments used to date in cancer care. As a leader in the development of novel therapeutics, Dr. Talpaz has unique experience in the building of Phase I clinical trial programs. In addition to expanding U-M’s program in hematologic malignances, he will be establishing a Phase I therapeutics program at the Cancer Center.
Dr. Talpaz joined U-M in 2006, from M.D. Anderson Cancer Center in Houston, where he was professor of medicine and held the David Bruton Chair for Cancer Research. He has authored or co-authored nearly 400 articles in top national journals and textbooks, and is a member of the American Society of Hematology and the NCCN Chronic Myelogenous Leukemia Guidelines Panel.'' Extract of http://www.cancer.med.umich.edu/about/leadership.shtml |
 |
Dr. Moshe Talpaz, University of Michigan Health System, Ann Arbor
Provocative Questions For CML Patients and Their Doctors (With Dr. Talpaz) VIDEO
December 5, 2010, from Patient Power , ASH 2010, Orlando
Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
November 19, 2010, Leukemia
